The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation
Open accessAbstract
SUMMARY MicroRNAs are frequently deregulated in cancer. Here we show that miR-22 is upregulated in myelodysplastic syndrome (MDS) and leukemia, and its aberrant expression correlates with poor survival. To explore its role in hematopoietic stem cell function and malignancy, we generated transgenic mice conditionally expressing miR-22 in the hematopoietic compartment. These mice displayed reduced levels of global 5-hydroxymethylcytosine (5-hmC) and increased hematopoietic stem cell self-renewal, accompanied by defective differentiation. Conversely, miR-22 inhibition blocked proliferation in both mouse and human leukemic cells. Over time, miR-22 transgenic mice developed MDS and hematological malignancies. We also identify TET2 as a key target of miR-22 in this context. Ectopic expression of TET2 suppressed the miR-22-incuced phenotypes. Downregulation of TET2 protein also correlated with poor clinical outcomes and miR-22 overexpression in MDS patients. Our results therefore identify miR-22 as a potent proto-oncogene, and suggest that aberrations in the miR-22-TET2 regulatory network are common in hematopoietic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
miRBase: microRNA sequences, targets and gene nomenclature
Griffiths-Jones, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj112 · Cited by 3,950
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
MicroRNAs Modulate Hematopoietic Lineage Differentiation
Chen, C.-Z., Li, L., Lodish, H. F., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1091903 · Cited by 3,257 · cited 18×
“Likewise, emerging evidence demonstrated no significant prognostic association between TET2 mutations in MDS patients and WHO subtypes, the International Prognostic Scoring System (IPSS) score, cytogenetic status, or transformation to AML (Kosmider et al., 2009; Smith et al., 2010).”
BackgroundInfluentialFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationThe microRNA.org resource: targets and expression
Betel, D., Wilson, M., Gabow, A., Marks, D. S., & Sander, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm995 · Cited by 2,503
Ito, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 2×
“Finally, since the technology to inhibit miRNAs for therapy is rapidly evolving (Elmén et al., 2008; Stenvang et al., 2008), this will impact treatment options for a range of diseases and disorders in the years to come.”
BackgroundTherapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation
Ficz, G., Branco, M. R., Seisenberger, S., Santos, F., Krueger, F., Hore, T. A., Marques, C. J., Andrews, S., & Reik, W. (2011) · Nature · doi:10.1038/nature10008 · Cited by 1,133
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., et al. (2006) · Nature · doi:10.1038/nature04747 · Cited by 817
Uncovering the role of 5-hydroxymethylcytosine in the epigenome
Branco, M. R., Ficz, G., & Reik, W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3080 · Cited by 766 · cited 1×
“TET2 catalyzes the oxidation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and is known to control hematopoiesis, presumably by regulating gene expression through its effect on DNA methylation (Branco et al., 2012; Ito et al., 2011; Ko et al., 2010; Shih et al., 2012).”
BackgroundMicroRNAs: key regulators of stem cells
Gangaraju, V. K., & Lin, H. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2621 · Cited by 734
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B. E., Yang, F.-C., & Xu, M. (2011) · Blood · doi:10.1182/blood-2010-12-325241 · Cited by 671
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
A continuum model for tumour suppression
Berger, A. H., Knudson, A. G., & Pandolfi, P. P. (2011) · Nature · doi:10.1038/nature10275 · Cited by 501
Self-citationSong, S. J., Poliseno, L., Song, M. S., Ala, U., Webster, K., Ng, C., Beringer, G., Brikbak, N. J., Yuan, X., Cantley, L. C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.026 · Cited by 491
Self-citationPoliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., Sportoletti, P., Varmeh, S., Egia, A., Fedele, G., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000594 · Cited by 410
Self-citationMicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 403
Self-citationA genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
Di Bernardo, M. C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., Sullivan, K., Vijayakrishnan, J., Wang, Y., Pittman, A. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.219 · Cited by 357
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 355
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276
Tefferi, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Patnaik, M. M., Hanson, C. A., Pardanani, A., Gilliland, D. G., & Levine, R. L. (2009) · Leukemia · doi:10.1038/leu.2009.59 · Cited by 268
Smith, A. E., Mohamedali, A. M., Kulasekararaj, A., Lim, Z., Gäken, J., Lea, N. C., Przychodzen, B., Mian, S. A., Nasser, E. E., Shooter, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 224
The utility of LNA in microRNA-based cancer diagnostics and therapeutics
Stenvang, J., Silahtaroglu, A. N., Lindow, M., Elmen, J., & Kauppinen, S. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.01.004 · Cited by 198
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.
Zhang, Y., Roccaro, A., Rombaoa, C., Flores, L., Obad, S., Fernandes, S., Sacco, A., Liu, Y., Ngo, H., Quang, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410647 · Cited by 144
Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia
Yamazaki, J., Taby, R. F., Vasanthakumar, A., Macrae, T. A., Ostler, K. R., Shen, L., Kantarjian, H. M., Estecio, M. R., Jelínek, J., Godley, L. A., et al. (2012) · Epigenetics · doi:10.4161/epi.7.2.19015 · Cited by 125
Patsos, G., Germann, A., Gebert, J. F., & Dihlmann, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24905 · Cited by 99
Kallin, E. M., Rodríguez-Ubreva, J., Christensen, J., Cimmino, L., Aifantis, I., Helin, K., Ballestar, E., & Graf, T. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.007 · Cited by 92 · cited 1×
“To further understand the consequences of repression of TET2 by miR-22 in hematopoiesis, we next examined the effects of miR-22 overexpression on putative targets of TET2 (Kallin et al., 2012; Ko et al., 2010; Yamazaki et al., 2012).”
BackgroundMerkerová, M. D., Krejčík, Z., Votavová, H., Beličková, M., Vašíková, A., & Čermák, J. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.209 · Cited by 76
MicroRNA programs in normal and aberrant stem and progenitor cells
Arnold, C. P., Tan, R., Zhou, B., Yue, S.-B., Schaffert, S., Biggs, J. R., Doyonnas, R., Lo, M.-C., Perry, J. M., Renault, V. M., et al. (2011) · Genome Research · doi:10.1101/gr.111385.110 · Cited by 65
Wang, J., Xiang, G., Zhang, K., & Zhou, Y. (2012) · Biotechnology Letters · doi:10.1007/s10529-012-1018-0 · Cited by 15
Cited by
TET-mediated active DNA demethylation: mechanism, function and beyond
Wu, X., & Zhang, Y. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.33 · Cited by 1,661
Reversing DNA Methylation: Mechanisms, Genomics, and Biological Functions
Wu, H., & Zhang, Y. (2014) · Cell · doi:10.1016/j.cell.2013.12.019 · Cited by 1,065
“Distributions of 5fC and 5caC were determined by antibody (5fC/5caC DIP) (Shen et al., 2013) or chemical tagging (fC-Seal) (Song et al., 2013a) methods.”
InfluentialMetabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Self-citationHeerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., & Sarkar, S. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0048-3 · Cited by 739
MicroRNAs as regulatory elements in immune system logic
Mehta, A., & Baltimore, D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.40 · Cited by 704
Metadata
- Authors
- Song, S. J., Ito, K., Ala, U., Kats, L., Webster, K., Sun, S. M., Jongen-Lavrencic, M., Manova-Todorova, K., Teruya-Feldstein, J., Avigan, D. E., Delwel, R., & Pandolfi, P. P.
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 13
- Issue
- 1
- Pages
- 87-101
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W2053930062
- Cited by
- 326
- References
- 46
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.